|
KR20170044172A
|
|
Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds
|
|
WO2016026912A1
|
|
Methods of treating lymphoma using thienotriazolodiazepine compounds
|
|
AU2015273032A1
|
|
Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
|
|
WO2015169953A1
|
|
Method of treating glioma using thienotriazolodiazepine compounds
|
|
EP3139959A1
|
|
Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds
|
|
MX2016014301A
|
|
Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds.
|
|
WO2016156905A1
|
|
Pharmaceutical doses for a bromodomain and extraterminal protein (bet) inhibitor
|
|
EP3074019A1
|
|
Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds
|
|
US2016158246A1
|
|
Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
|
|
AU2013340483A1
|
|
Pharmaceutical formulation containing thienotriazolodiazepine compounds
|
|
AU2013283378A1
|
|
Method of treating lymphoma using thienotriazolodiazepine compounds
|
